English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tuberculosis (TB) till date remains one of the most dreaded infectious diseases, registering an alarming death count nearing 1.8 million every year worldwide. Latest estimates of World Health Organization (WHO) adds more to this disturbing tale, approximately 10.4 million people across the World are infected with tuberculosis in 2016 [1]. The growing number of infected patients can also be related to increased incidence of HIV as tuberculosis remains one of the most common co-infection and also main cause of mortality in HIV patients [2]. What further complicates the treatment of tuberculosis is emergence of multidrug-resistant tuberculosis (MDR-TB), extensively drug resistant tuberculosis (XDR-TB) and most virulent totally drug resistant tuberculosis (TDR-TB) [3,4]. The current regimen of antituberculosis drugs target different biological pathways important for the survival of the Mycobacterium tuberculosis (MTB) and quest for new pathways that can be targeted is on full swing [5]. With most of the drugs in use are rendered ineffective or less effective due to emergence of drug resistant strains, developing new strategies and finding new targets is a pressing need to mitigate the risk of drug resistance [6,7]. One such pathway that has garnered lot of attention lately is energy metabolism in MTB and this obviously is credited to the US FDA approval for bedaquiline, reported to inhibit F1F0 ATP synthase [8,9]. Replicating or non-replicating tuberculi need in silico Quest Guided by Physico-Chemical Descriptors of Bedaquiline for New Scaffolds with Potential Inhibitory Capacity against Homology Model of Mycobacterium F1F0 ATP Synthase

asian journal of chemistry/asian journal of chemistry

in silico Quest Guided by Physico-Chemical Descriptors of Bedaquiline for New Scaffolds with Potential Inhibitory Capacity against Homology Model of Mycobacterium F1F0 ATP Synthase